Price$33.51-0.24 (-0.71%)
01:30 PM07:45 PM
News · 26 weeks91-61%
2026-04-192026-10-11
Mix5990d
- Insider31(53%)
- SEC Filings10(17%)
- Earnings8(14%)
- Other8(14%)
- Analyst2(3%)
Latest news
25 items- ANALYSTRoivant Sciences downgraded by Wolfe ResearchWolfe Research downgraded Roivant Sciences from Outperform to Peer Perform
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Roivant Sciences Ltd.SCHEDULE 13D/A - Roivant Sciences Ltd. (0001635088) (Filed by)
- INSIDERSEC Form 4 filed by Roivant Sciences Ltd.4 - Roivant Sciences Ltd. (0001635088) (Reporting)
- INSIDERSEC Form 4 filed by Roivant Sciences Ltd.4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,583,774 units (SEC Form 4) to satisfy withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident and Vant Chair Torti Frank increased direct ownership by 0.30% to 13,495,893 units (SEC Form 4) to satisfy withholding obligation4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh covered exercise/tax liability with 46,879 shares, decreasing direct ownership by 0.25% to 18,583,860 units (SEC Form 4) to satisfy withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & Immunovant CEO Venker Eric sold $7,324,000 worth of shares (200,000 units at $36.62) as part of a pre-agreed trading plan and exercised 200,000 shares at a strike of $3.85 (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- PRRoivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusImmunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in CLEIMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studiesAll other clinical development timelines remain on track BASEL, Switzerland and LONDON and NEW
- PRImmunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusImmunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in CLEIMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studiesAll other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE
- INSIDERChief Accounting Officer Humes Jennifer covered exercise/tax liability with 3,880 shares, decreasing direct ownership by 4% to 106,419 units (SEC Form 4) (for tax liability)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCFO Pulik Richard covered exercise/tax liability with 2,129 shares, decreasing direct ownership by 0.78% to 269,681 units (SEC Form 4) (withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Manchester Keith S was granted 5,054 shares, increasing direct ownership by 0.29% to 1,753,457 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Gold Daniel Allen was granted 5,054 shares, increasing direct ownership by 0.06% to 8,965,815 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Oren Ilan was granted 5,054 shares, increasing direct ownership by 4% to 123,680 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Momtazee James C was granted 5,054 shares, increasing direct ownership by 5% to 111,959 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Fitzgerald Meghan was granted 5,054 shares, increasing direct ownership by 14% to 41,162 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Epperly Melissa B, was granted 5,054 shares, increasing direct ownership by 51% to 14,954 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- INSIDERDirector Epperly Melissa B, sold $196,230 worth of shares (4,938 units at $39.74) as part of a pre-agreed trading plan, decreasing direct ownership by 33% to 9,900 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Fitzgerald Meghan sold $203,152 worth of shares (5,112 units at $39.74) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,108 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- ANALYSTStifel initiated coverage on Roivant Sciences with a new price targetStifel initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $51.00
- SECSEC Form 144 filed by Roivant Sciences Ltd.144 - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERDirector Gold Daniel Allen covered exercise/tax liability with 5,133 shares, decreasing direct ownership by 0.06% to 8,960,761 units (SEC Form 4) (withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Oren Ilan covered exercise/tax liability with 2,378 shares, decreasing direct ownership by 2% to 118,626 units (SEC Form 4) (withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
ROIV FAQ
6 questionsWhat does Roivant Sciences Ltd. do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Where does ROIV stock trade?
Roivant Sciences Ltd. (ROIV) is listed on NASDAQ.What sector and industry is ROIV in?
Roivant Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ROIV?
Roivant Sciences Ltd. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-10-12. Recent price targets range from $1400.00 to $3500.00.What companies are similar to ROIV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ROIV side-by-side with any of them on Quantisnow.How can I track ROIV on Quantisnow?
Quantisnow aggregates Roivant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ROIV to receive live email and push alerts on every new disclosure.